Cigna Corporation

🇺🇸New York Stock Exchange
Back to all articles
Cigna Corporation stock analysis CI overview
Slightly Bullish +25

The The Cigna Group (NYSE:CI) First-Quarter Results Are Out And Analysts Have Published New Forecasts

📈 Cigna Group (NYSE:CI) shares rose 2.6% to $283 following the release of respectable first-quarter earnings.

💰 Statutory earnings of $6.26 per share came in roughly in line with analyst forecasts.

💵 Total revenues reached $68 billion, which is 3.5% ahead of what analysts predicted.

🔮 Analysts are now forecasting 2026 revenues to hit $282.9 billion, a slight increase from the previous estimate of $281.8 billion.

⬆️ Per-share earnings for 2026 are expected to rise 6.2% to $25.34 compared to the prior consensus of $24.18.

📉 The consensus price target remains unchanged at $339 despite the improved earnings outlook.

🎯 Analyst valuations range widely, with the most bullish at $378 and the most bearish at $290 per share.

📊 Expected revenue growth for Cigna to end of 2026 is projected at 2.4% annually on an annualized basis.

💹 This anticipated growth rate represents a significant slowdown compared to the company's historical 12% average over the past five years.

🏆 The wider industry is expected to grow at 4.7% annually, outpacing Cigna's projected revenue growth.

⚠️ There is one specific warning sign for Cigna Group that investors should be aware of according to the article.

📝 The long-term prospects of the business are deemed more relevant than next year's specific earnings results.

Bullish Signals
  • Cigna Group (CI) shares rose 2.6% to close at US$283 following the release of respectable first-quarter results.
  • Revenues of US$68b came in 3.5% ahead of analyst predictions, demonstrating stronger than expected top-line performance.
  • Analysts are now forecasting 2026 per-share earnings to rise 6.2% to US$25.34, marking a consensus upgrade compared to prior estimates of US$24.18.
  • There are 17 analysts covering the company with an average rating of Buy and a mean price target of $340.96.
  • The consensus forecast shows per-share earnings potential increasing to US$25.34, reflecting growing optimism about the company's earnings trajectory.
Risk Factors
  • Cigna Group's revenue growth is expected to slow down substantially to 2.4% annually through 2026, compared to a historical rate of 12% over the past five years.
  • The company is forecasted to underperform its wider industry peers, which are expected to see aggregate annual revenue growth of 4.7% in comparison to Cigna's 2.4%.
  • Despite improved earnings outlook and a consensus upgrade, the price target remained unchanged at US$339, indicating limited long-term impact on shareholder value creation from recent results.
  • The range of analyst estimates is narrow, with the most bearish valuation at US$290 significantly lower than the average rating, suggesting persistent downside risk perception among investors.
Full Analysis
The Cigna Group (NYSE:CI) reported first-quarter results that led its shares to rise 2.6% to close at US$283, with statutory earnings of US$6.26 per share meeting analyst expectations and revenues of US$68 billion coming in 3.5% ahead of forecasts. Following the report, 17 analysts updated their forecasts for 2026, raising projected per-share earnings to US$25.34 from a previous expectation of US$24.18, representing a 6.2% increase. In contrast, revenue projections for 2026 remain relatively stable at approximately US$282.9 billion, compared to the prior estimate of US$281.8 billion. This divergence highlights an improved sentiment regarding earnings potential without significant revisions to top-line growth expectations for that fiscal year. Despite the EPS upgrade, the consensus price target remained unchanged at US$339, suggesting analysts view the latest results as having limited immediate impact on long-term value creation. Analyst estimates for Cigna Group currently range widely from a most bullish valuation of US$378 to a bearish stance at US$290 per share, though the narrow spread may indicate a high degree of consensus on valuation difficulty. When comparing future performance to historical trends and industry peers, revenue growth is expected to decelerate substantially; annualized growth through 2026 is projected at only 2.4%, compared to a 12% historical average over the past five years and an industry-wide expectation of 4.7% annual growth. The primary takeaway from this analysis is the clear improvement in earnings sentiment, even though revenue forecasts indicate Cigna will underperform the wider industry sector in the coming years. While long-term prospects extending to 2028 are considered more relevant than next year's earnings alone, one specific warning sign was identified by the analysts that investors should note before forming a complete investment picture. Overall, the stock maintains an average rating of "Buy" with a mean price target hovering around US$341, reflecting a mixed outlook where operational efficiency may offset slower revenue expansion in the medium term. Disclaimer: This summary is based on the provided article text and does not constitute financial advice or a recommendation to buy or sell any stock. The analysis utilizes historical data and analyst forecasts but may not factor in the latest price-sensitive announcements or qualitative material. Simply Wall St has no position in Cigna Group, and this content is general in nature intended for informational purposes only.